Allergan gains US FDA nod for Botox in overactive bladder
This article was originally published in Scrip
Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.
You may also be interested in...
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.